Eribulin mesylate vs Utidelone

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HR+/HER2- Metastatic Breast Cancer

Shared mechanism: Tubulin / microtubules · full HR+/HER2- Metastatic Breast Cancer pipeline

Eribulin mesylate

Marketed by Eisai and partners

Approved in HR+/HER2- Metastatic Breast Cancersmall molecule
Partial signal

NCT00337103 · Phase 3 · completed

Study 301 was an open-label, randomized Phase 3 trial of eribulin vs capecitabine in 1,102 women with metastatic breast cancer previously treated with an anthracycline and a taxane. The co-primary endpoints were overall survival and progression-free survival. Neither was significant: OS HR 0.88 (95% CI 0.77 to 1.00, P = .056) and PFS HR 1.08 (95% CI 0.93 to 1.25, P = .30). The paper concludes eribulin was not shown to be superior on either endpoint, so the primary was missed. Source: the peer-reviewed paper (Kaufman et al., J Clin Oncol 2015).

Next expected readout: June 2027 · NCT06942234 (registry estimate)

Reported efficacy

Progression-Free Survival (PFS) of Eribulin Arm by tumor assessment : Time to disease progression (Baseline until date of recorded disease progression or death, or up to 2 years); Progression-Free Survival (PFS) of Vinorelbine Arm by tumor assessment: Time to disease progression (Baseline until date of recorded disease progression or death, or up to 2 years); Maximum observed plasma concentration (Cmax) of Eribulin Arm in a minimum of 15 subjects (Day 1 and Day 8); Time at which the highest drug concentration occurs (tmax) of Eribulin Arm in a minimum of 15 subjects (Day 1 and Day 8); Area under the plasma concentration-time curve (AUC) of Eribulin Arm in a minimum of 15 subjects (Day 1 and Day 8); Terminal phase rate constant (lambda Z) of Eribulin Arm in a minimum of 15 subjects (Day 1 and Day 8); Terminal elimination phase half-life (t1/2) of Eribulin Arm in a minimum of 15 subjects (Day 1 and Day 8); Distribution volume at steady-state (Vss) of Eribulin Arm in a minimum of 15 subjects (Day 1 and Day 8); Total clearance (CL) of Eribulin Arm in a minimum of 15 subjects (Day 1 and Day 8): Progression-Free Survival, eribulin vs vinorelbine (independent tumor assessment): HR 0.80 (95% CI 0.65-0.98, P=0.036) in favor of eribulin; median PFS 2.8 months in both arms (met)

Result source: NCT02225470

Utidelone

Marketed by Beijing Biostar Pharmaceuticals

Phase 3 in HR+/HER2- Metastatic Breast Cancersmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2026 · NCT05398861 (registry estimate)

No aligned efficacy figure on record for this race.

Results for HR+/HER2- Metastatic Breast Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointEribulin mesylateUtidelone
PFS, median4.1 vs 4.2vs Capecitabine1.4 mg/m^2 · n 554NCT00337103
9 other results
—Trial running · NCT05172518
OS, median15.9 vs 14.5vs Capecitabine1.4 mg/m^2 · n 554NCT00337103
5 other results
—Trial running · NCT05172518
ORR11% vs 11.5%vs Capecitabine1.4 mg/m^2 · n 554NCT00337103
8 other results
—Trial running · NCT05172518
Clinical benefit rate57.1%b1.4 mg/m^2 · n 42NCT01323530—Trial running · NCT05172518

PFS, median

Eribulin mesylate
4.1 vs 4.2vs Capecitabine1.4 mg/m^2 · n 554NCT00337103
9 other results
Utidelone
—Trial running · NCT05172518

OS, median

Eribulin mesylate
15.9 vs 14.5vs Capecitabine1.4 mg/m^2 · n 554NCT00337103
5 other results
Utidelone
—Trial running · NCT05172518

ORR

Eribulin mesylate
11% vs 11.5%vs Capecitabine1.4 mg/m^2 · n 554NCT00337103
8 other results
Utidelone
—Trial running · NCT05172518

Clinical benefit rate

Eribulin mesylate
57.1%b1.4 mg/m^2 · n 42NCT01323530
Utidelone
—Trial running · NCT05172518
  1. b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Utidelone: no structured comparison results are available for HR+/HER2- Metastatic Breast Cancer.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Eribulin mesylate: 4 of 4 rows · Utidelone: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricEribulin mesylate
Dropout rate
n/a: no completion milestone1.4 mg/m^2a
NCT00337103 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 35 more results
12.9%1.4 mg/m^2
NCT01961544 · Phase 4 · registry result, not featured evidence
4.3%
NCT03051659 · Phase 2 · registry result, not featured evidence · combination
0%
NCT02581839 · Phase 2 · registry result, not featured evidence
13.2%
NCT01908101 · Phase 2 · registry result, not featured evidence
n/a: no completion milestone1.4 mg/m^2
NCT02481050 · Phase 2 · registry result, not featured evidence
—Cohort A: Triple-negative Breast C
NCT01401959 · Phase 2 · registry result, not featured evidence
1.9%Cohort A: Triple-negative Breast C
NCT01401959 · Phase 2 · registry result, not featured evidence
0%Cohort B: ER/PR Positive/HER2-nega
NCT01401959 · Phase 2 · registry result, not featured evidence
—Cohort C: HER2 Positive Breast Can
NCT01401959 · Phase 2 · registry result, not featured evidence
0%Cohort C: HER2-positive Breast Can
NCT01401959 · Phase 2 · registry result, not featured evidence
—
NCT01527487 · Phase 2 · registry result, not featured evidence · combination
0%Cohort 1: HR+/HER2-
NCT01827787 · Phase 2 · registry result, not featured evidence · combination
0%Cohort 2: TNBC
NCT01827787 · Phase 2 · registry result, not featured evidence
15.1%
NCT02061085 · Phase 2 · registry result, not featured evidence · monotherapy
50%
NCT01268150 · Phase 2 · registry result, not featured evidence
8.6%
NCT00965523 · Phase 2 · registry result, not featured evidence
0%1.4 mg/m2
NCT01554371 · Phase 1/2 · registry result, not featured evidence · combination
0%1.1 mg/m2
NCT01554371 · Phase 1/2 · registry result, not featured evidence · combination
0%Phase II: Eribulin Combination w/
NCT01554371 · Phase 1/2 · registry result, not featured evidence · combination
0%1000 mg/day
NCT01596751 · Phase 1/2 · registry result, not featured evidence · combination
0%1000 mg/day
NCT01596751 · Phase 1/2 · registry result, not featured evidence · combination
—800 mg/day
NCT01596751 · Phase 1/2 · registry result, not featured evidence · combination
0%800 mg/day
NCT01596751 · Phase 1/2 · registry result, not featured evidence · combination
0%800 mg/day
NCT01596751 · Phase 1/2 · registry result, not featured evidence · combination
0%600 mg/day
NCT01596751 · Phase 1/2 · registry result, not featured evidence · combination
0%600 mg/day
NCT01596751 · Phase 1/2 · registry result, not featured evidence · combination
0%400 mg/day
NCT01596751 · Phase 1/2 · registry result, not featured evidence · combination
20%2.0 mg/m^2
NCT01323530 · Phase 1/2 · registry result, not featured evidence · combination
33.3%1.6 mg/m^2
NCT01323530 · Phase 1/2 · registry result, not featured evidence · combination
50%1.4 mg/m^2
NCT01323530 · Phase 1/2 · registry result, not featured evidence · combination
—1.4 mg/m^2
NCT01323530 · Phase 1/2 · registry result, not featured evidence · combination
37.5%1.2 mg/m^2
NCT01323530 · Phase 1/2 · registry result, not featured evidence · combination
50%1.1 mg/m^2
NCT01323530 · Phase 1/2 · registry result, not featured evidence · combination
0%0.7 mg/m^2
NCT01323530 · Phase 1/2 · registry result, not featured evidence · combination
44.4%
NCT01142661 · Phase na · registry result, not featured evidence
Discontinued due to AEs
8.1%1.4 mg/m^2a
NCT00337103 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 35 more results
1%1.4 mg/m^2
NCT01961544 · Phase 4 · registry result, not featured evidence
—
NCT03051659 · Phase 2 · registry result, not featured evidence · combination
—
NCT02581839 · Phase 2 · registry result, not featured evidence
—
NCT01908101 · Phase 2 · registry result, not featured evidence
1.7%1.4 mg/m^2
NCT02481050 · Phase 2 · registry result, not featured evidence
—Cohort A: Triple-negative Breast C
NCT01401959 · Phase 2 · registry result, not featured evidence
—Cohort A: Triple-negative Breast C
NCT01401959 · Phase 2 · registry result, not featured evidence
—Cohort B: ER/PR Positive/HER2-nega
NCT01401959 · Phase 2 · registry result, not featured evidence
—Cohort C: HER2 Positive Breast Can
NCT01401959 · Phase 2 · registry result, not featured evidence
—Cohort C: HER2-positive Breast Can
NCT01401959 · Phase 2 · registry result, not featured evidence
—
NCT01527487 · Phase 2 · registry result, not featured evidence · combination
—Cohort 1: HR+/HER2-
NCT01827787 · Phase 2 · registry result, not featured evidence · combination
—Cohort 2: TNBC
NCT01827787 · Phase 2 · registry result, not featured evidence
15.1%
NCT02061085 · Phase 2 · registry result, not featured evidence · monotherapy
5.4%
NCT01268150 · Phase 2 · registry result, not featured evidence
—
NCT00965523 · Phase 2 · registry result, not featured evidence
—1.4 mg/m2
NCT01554371 · Phase 1/2 · registry result, not featured evidence · combination
—1.1 mg/m2
NCT01554371 · Phase 1/2 · registry result, not featured evidence · combination
—Phase II: Eribulin Combination w/
NCT01554371 · Phase 1/2 · registry result, not featured evidence · combination
—1000 mg/day
NCT01596751 · Phase 1/2 · registry result, not featured evidence · combination
—1000 mg/day
NCT01596751 · Phase 1/2 · registry result, not featured evidence · combination
—800 mg/day
NCT01596751 · Phase 1/2 · registry result, not featured evidence · combination
—800 mg/day
NCT01596751 · Phase 1/2 · registry result, not featured evidence · combination
—800 mg/day
NCT01596751 · Phase 1/2 · registry result, not featured evidence · combination
—600 mg/day
NCT01596751 · Phase 1/2 · registry result, not featured evidence · combination
—600 mg/day
NCT01596751 · Phase 1/2 · registry result, not featured evidence · combination
—400 mg/day
NCT01596751 · Phase 1/2 · registry result, not featured evidence · combination
0%2.0 mg/m^2
NCT01323530 · Phase 1/2 · registry result, not featured evidence · combination
0%1.6 mg/m^2
NCT01323530 · Phase 1/2 · registry result, not featured evidence · combination
33.3%1.4 mg/m^2
NCT01323530 · Phase 1/2 · registry result, not featured evidence · combination
—1.4 mg/m^2
NCT01323530 · Phase 1/2 · registry result, not featured evidence · combination
25%1.2 mg/m^2
NCT01323530 · Phase 1/2 · registry result, not featured evidence · combination
0%1.1 mg/m^2
NCT01323530 · Phase 1/2 · registry result, not featured evidence · combination
0%0.7 mg/m^2
NCT01323530 · Phase 1/2 · registry result, not featured evidence · combination
22.2%
NCT01142661 · Phase na · registry result, not featured evidence
Serious AEs
17.5%1.4 mg/m^2a
NCT00337103 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 35 more results
19.8%1.4 mg/m^2
NCT01961544 · Phase 4 · registry result, not featured evidence
61.4%
NCT03051659 · Phase 2 · registry result, not featured evidence · combination
33.3%
NCT02581839 · Phase 2 · registry result, not featured evidence
3.4%
NCT01908101 · Phase 2 · registry result, not featured evidence
24.1%1.4 mg/m^2
NCT02481050 · Phase 2 · registry result, not featured evidence
15.1%Cohort A: Triple-negative Breast C
NCT01401959 · Phase 2 · registry result, not featured evidence
—Cohort A: Triple-negative Breast C
NCT01401959 · Phase 2 · registry result, not featured evidence
2.4%Cohort B: ER/PR Positive/HER2-nega
NCT01401959 · Phase 2 · registry result, not featured evidence
9.7%Cohort C: HER2 Positive Breast Can
NCT01401959 · Phase 2 · registry result, not featured evidence
—Cohort C: HER2-positive Breast Can
NCT01401959 · Phase 2 · registry result, not featured evidence
7.4%
NCT01527487 · Phase 2 · registry result, not featured evidence · combination
48.9%Cohort 1: HR+/HER2-
NCT01827787 · Phase 2 · registry result, not featured evidence · combination
34.2%Cohort 2: TNBC
NCT01827787 · Phase 2 · registry result, not featured evidence
20.8%
NCT02061085 · Phase 2 · registry result, not featured evidence · monotherapy
30.4%
NCT01268150 · Phase 2 · registry result, not featured evidence
17.3%
NCT00965523 · Phase 2 · registry result, not featured evidence
33.3%1.4 mg/m2
NCT01554371 · Phase 1/2 · registry result, not featured evidence · combination
0%1.1 mg/m2
NCT01554371 · Phase 1/2 · registry result, not featured evidence · combination
13.2%Phase II: Eribulin Combination w/
NCT01554371 · Phase 1/2 · registry result, not featured evidence · combination
35.3%1000 mg/day
NCT01596751 · Phase 1/2 · registry result, not featured evidence · combination
50%1000 mg/day
NCT01596751 · Phase 1/2 · registry result, not featured evidence · combination
63.6%800 mg/day
NCT01596751 · Phase 1/2 · registry result, not featured evidence · combination
33.3%800 mg/day
NCT01596751 · Phase 1/2 · registry result, not featured evidence · combination
25%800 mg/day
NCT01596751 · Phase 1/2 · registry result, not featured evidence · combination
60%600 mg/day
NCT01596751 · Phase 1/2 · registry result, not featured evidence · combination
33.3%600 mg/day
NCT01596751 · Phase 1/2 · registry result, not featured evidence · combination
75%400 mg/day
NCT01596751 · Phase 1/2 · registry result, not featured evidence · combination
20%2.0 mg/m^2
NCT01323530 · Phase 1/2 · registry result, not featured evidence · combination
66.7%1.6 mg/m^2
NCT01323530 · Phase 1/2 · registry result, not featured evidence · combination
66.7%1.4 mg/m^2
NCT01323530 · Phase 1/2 · registry result, not featured evidence · combination
23.8%1.4 mg/m^2
NCT01323530 · Phase 1/2 · registry result, not featured evidence · combination
25%1.2 mg/m^2
NCT01323530 · Phase 1/2 · registry result, not featured evidence · combination
50%1.1 mg/m^2
NCT01323530 · Phase 1/2 · registry result, not featured evidence · combination
66.7%0.7 mg/m^2
NCT01323530 · Phase 1/2 · registry result, not featured evidence · combination
77.8%
NCT01142661 · Phase na · registry result, not featured evidence
Most frequent reported AEs
1.4 mg/m^2a
neutropenia 53.7%
alopecia 34.6%
leukopenia 31.4%
NCT00337103 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 33 more results
1.4 mg/m^2
neutropenia 91.1%
alopecia 45.5%
decreased appetite 40.6%
NCT01961544 · Phase 4 · registry result, not featured evidence
fatigue 88.6%
nausea 56.8%
alopecia 54.5%
NCT03051659 · Phase 2 · registry result, not featured evidence · combination
fatigue 88.9%
anemia 66.7%
constipation 66.7%
NCT02581839 · Phase 2 · registry result, not featured evidence
neutropenia 22%
white blood cell decreased 6.8%
fatigue 5.1%
NCT01908101 · Phase 2 · registry result, not featured evidence
1.4 mg/m^2
fatigue 55.2%
alopecia 50%
neutropenia 43.1%
NCT02481050 · Phase 2 · registry result, not featured evidence
fatigue 63.5%
neutrophil count decreased 50%
peripheral sensory neuropathy 46.2%
NCT01401959 · Phase 2 · registry result, not featured evidence
fatigue 61.9%
peripheral sensory neuropathy 59.5%
leukopenia 54.8%
NCT01401959 · Phase 2 · registry result, not featured evidence
fatigue 74.2%
neutrophil count decreased 54.8%
anemia 51.6%
NCT01401959 · Phase 2 · registry result, not featured evidence
fatigue 74.1%
nausea 61.1%
alopecia 59.3%
NCT01527487 · Phase 2 · registry result, not featured evidence · combination
fatigue 64.4%
alopecia 57.8%
nausea 37.8%
NCT01827787 · Phase 2 · registry result, not featured evidence · combination
fatigue 65.8%
nausea 44.7%
alopecia 39.5%
NCT01827787 · Phase 2 · registry result, not featured evidence
alopecia 34%
nausea 26.4%
anorexia and bulimia syndrome 18.9%
NCT02061085 · Phase 2 · registry result, not featured evidence · monotherapy
alopecia 83.9%
neutropenia 71.4%
fatigue 64.3%
NCT01268150 · Phase 2 · registry result, not featured evidence
leukopenia 98.8%
neutropenia 98.8%
alopecia 58%
NCT00965523 · Phase 2 · registry result, not featured evidence
1.4 mg/m2
nausea 100%
alopecia 66.7%
anorexia 66.7%
NCT01554371 · Phase 1/2 · registry result, not featured evidence · combination
1.1 mg/m2
constipation 100%
nausea 100%
arthralgia 66.7%
NCT01554371 · Phase 1/2 · registry result, not featured evidence · combination
dyspnea 47.4%
back pain 31.6%
pain in extremity 28.9%
NCT01554371 · Phase 1/2 · registry result, not featured evidence · combination
1000 mg/day
fatigue 58.8%
nausea 52.9%
neutrophil count decreased 52.9%
NCT01596751 · Phase 1/2 · registry result, not featured evidence · combination
1000 mg/day
anorexia 66.7%
nausea 66.7%
alanine aminotransferase increased 33.3%
NCT01596751 · Phase 1/2 · registry result, not featured evidence · combination
800 mg/day
fatigue 63.6%
aspartate aminotransferase increased 45.5%
alanine aminotransferase increased 36.4%
NCT01596751 · Phase 1/2 · registry result, not featured evidence · combination
800 mg/day
rash maculo-papular 50%
aspartate aminotransferase increased 33.3%
fatigue 33.3%
NCT01596751 · Phase 1/2 · registry result, not featured evidence · combination
800 mg/day
alanine aminotransferase increased 75%
aspartate aminotransferase increased 75%
anorexia 50%
NCT01596751 · Phase 1/2 · registry result, not featured evidence · combination
600 mg/day
anorexia 60%
fatigue 60%
rash maculo-papular 60%
NCT01596751 · Phase 1/2 · registry result, not featured evidence · combination
600 mg/day
fatigue 33.3%
nausea 33.3%
neutrophil count decreased 33.3%
NCT01596751 · Phase 1/2 · registry result, not featured evidence · combination
400 mg/day
cough 75%
dyspnea 50%
fatigue 50%
NCT01596751 · Phase 1/2 · registry result, not featured evidence · combination
2.0 mg/m^2
decreased appetite 100%
nausea 80%
alopecia 60%
NCT01323530 · Phase 1/2 · registry result, not featured evidence · combination
1.6 mg/m^2
lethargy 66.7%
nausea 66.7%
diarrhoea 50%
NCT01323530 · Phase 1/2 · registry result, not featured evidence · combination
1.4 mg/m^2
nausea 100%
vomiting 100%
neutropenia 83.3%
NCT01323530 · Phase 1/2 · registry result, not featured evidence · combination
1.4 mg/m^2
neutropenia 81%
leukopenia 47.6%
alopecia 35.7%
NCT01323530 · Phase 1/2 · registry result, not featured evidence · combination
1.2 mg/m^2
diarrhoea 75%
nausea 50%
headache 37.5%
NCT01323530 · Phase 1/2 · registry result, not featured evidence · combination
1.1 mg/m^2
lethargy 66.7%
alopecia 50%
diarrhoea 50%
NCT01323530 · Phase 1/2 · registry result, not featured evidence · combination
0.7 mg/m^2
diarrhoea 66.7%
dyspnoea 66.7%
lethargy 66.7%
NCT01323530 · Phase 1/2 · registry result, not featured evidence · combination
fatigue 66.7%
constipation 44.4%
nausea 44.4%
NCT01142661 · Phase na · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 35 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Eribulin mesylate

Overall Survival 15.9 vs 14.46 Capecitabine months1.4 mg/m^2
time to event · months
NCT00337103 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 · converted to months from 484 days as posted
show 1 more result
13.4 vs 12.5 Eribulin Mesylate months
NCT03051659 · Phase 2 · registry result, not featured evidence · combination
PFS 4.14 vs 4.24 Capecitabine months1.4 mg/m^2
time to event · months
NCT00337103 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 · converted to months from 126 days as posted
show 2 more results
4.1 vs 4.2 Eribulin Mesylate months
NCT03051659 · Phase 2 · registry result, not featured evidence · combination
2.8 vs 2.8 vinorelbine months
NCT02225470 · Phase 3 · sponsor-reported, not registry data
ORR 11% (n=554) vs 11.5% (n=548) Capecitabine1.4 mg/m^2
responder rate · % of participants
NCT00337103 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
27% (n=44) vs 34% (n=44) Eribulin Mesylate
NCT03051659 · Phase 2 · registry result, not featured evidence · combination
Duration of Response 6.51 vs 10.84 Capecitabine months1.4 mg/m^2
time to event · months
NCT00337103 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 · converted to months from 198 days as posted
show 1 more result
0.6 vs 2.1 Eribulin Mesylate months
NCT03051659 · Phase 2 · registry result, not featured evidence · combination
Stable Disease 34.4% (n=96)1.4 mg/m^2
event count · % of participants
No placebo or comparator arm
SD
NCT01961544 · Phase 4 · registry result, not featured evidence · converted to % from 33 Participants as posted
Clinical Benefit 50% (n=44) vs 47.7% (n=44) Eribulin Mesylate
event count · % of participants
NCT03051659 · Phase 2 · registry result, not featured evidence · combination · converted to % from 22 Participants as posted
PFS 3mo 88.9% (n=9) @ 12wk
responder rate · % of participants
No placebo or comparator arm
NCT02581839 · Phase 2 · registry result, not featured evidence
show 1 more result
35.7% (n=31) @ 12wk
NCT01596751 · Phase 1/2 · registry result, not featured evidence · combination
ORR 12.3% (n=57)1.4 mg/m^2
responder rate · % of participants
No placebo or comparator arm
NCT02481050 · Phase 2 · registry result, not featured evidence
show 6 more results
42.9% (n=42)1.4 mg/m^2
NCT01323530 · Phase 1/2 · registry result, not featured evidence · combination
11.1% (n=9)
NCT02581839 · Phase 2 · registry result, not featured evidence
35.6% (n=45)
NCT01827787 · Phase 2 · registry result, not featured evidence · combination
13.2% (n=38)
NCT01827787 · Phase 2 · registry result, not featured evidence
28.6% (n=56)
NCT01268150 · Phase 2 · registry result, not featured evidence
16% (n=31)
NCT01596751 · Phase 1/2 · registry result, not featured evidence · combination
CNS Duration of Response 5.22 months
time to event · months
No placebo or comparator arm
NCT02581839 · Phase 2 · registry result, not featured evidence · converted to months from 22.6 weeks as posted
Clinical Benefit 55.6% (n=9) @ 12wk
event count · % of participants
No placebo or comparator arm
NCT02581839 · Phase 2 · registry result, not featured evidence · converted to % from 5 Participants as posted
show 1 more result
26.4% (n=53)*
NCT02061085 · Phase 2 · registry result, not featured evidence · monotherapy · converted to % from 14 Participants as posted
Overall Survival 12.9 months1.4 mg/m^2
time to event · months
No placebo or comparator arm
NCT02481050 · Phase 2 · registry result, not featured evidence
show 3 more results
15.7 months
NCT02581839 · Phase 2 · registry result, not featured evidence
20 months
NCT01827787 · Phase 2 · registry result, not featured evidence · combination
11.3 months
NCT01827787 · Phase 2 · registry result, not featured evidence
PFS 3.6 months1.4 mg/m^2
time to event · months
No placebo or comparator arm
NCT02481050 · Phase 2 · registry result, not featured evidence
show 6 more results
7.2 months*1.4 mg/m^2
NCT01323530 · Phase 1/2 · registry result, not featured evidence · combination · converted to months from 219 days as posted
3.5 months
NCT01908101 · Phase 2 · registry result, not featured evidence
6.2 months
NCT01827787 · Phase 2 · registry result, not featured evidence · combination
4 months
NCT01827787 · Phase 2 · registry result, not featured evidence
4.1 months
NCT02061085 · Phase 2 · registry result, not featured evidence · monotherapy
6.8 months
NCT01268150 · Phase 2 · registry result, not featured evidence

+ 16 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Eribulin mesylate's landscape · Utidelone's landscape